Oncolytic vaccinia virus combined with radiotherapy induces apoptotic cell death in sarcoma cells by down-regulating the inhibitors of apoptosis. by Wilkinson, MJ et al.
Oncotarget81208www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/             Oncotarget, 2016, Vol. 7, (No. 49), pp: 81208-81222
Oncolytic vaccinia virus combined with radiotherapy induces 
apoptotic cell death in sarcoma cells by down-regulating the 
inhibitors of apoptosis
Michelle J. Wilkinson1,2, Henry G. Smith1,2, Gráinne McEntee1, Joan Kyula-Currie1, 
Tim D. Pencavel1,2,*, David C. Mansfield1, Aadil A. Khan1, Victoria Roulstone1, 
Andrew J. Hayes2,3,*, Kevin J. Harrington1,3,*
1Targeted Therapy Team, Division of Cancer Biology, The Institute of Cancer Research, London, UK
2Sarcoma/Melanoma Unit, Dept of Academic Surgery, Royal Marsden Hospital NHS Foundation Trust, London, UK
3Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK
*These authors have contributed equally to this work
Correspondence to: Kevin Harrington email: Kevin.Harrington@icr.ac.uk
Keywords: Oncolytic virotherapy, Radiation, Soft tissue sarcoma
Received: May 20, 2016    Accepted: October 11, 2016    Published: October 22, 2016
ABSTRACT
Advanced extremity melanoma and sarcoma present a significant therapeutic 
challenge, requiring multimodality therapy to treat or even palliate disease. These 
aggressive tumours are relatively chemo-resistant, therefore new treatment 
approaches are urgently required. We have previously reported on the efficacy of 
oncolytic virotherapy (OV) delivered by isolated limb perfusion. In this report, we 
have improved therapeutic outcomes by combining OV with radiotherapy. In vitro, the 
combination of oncolytic vaccinia virus (GLV-1h68) and radiotherapy demonstrated 
synergistic cytotoxicity. This effect was not due to increased viral replication, but 
mediated through induction of intrinsic apoptosis. GLV-1h68 therapy downregulated 
the anti-apoptotic BCL-2 proteins (MCL-1 and BCL-XL) and the downstream inhibitors 
of apoptosis, resulting in cleavage of effector caspases 3 and 7. In an in vivo ILP 
model, the combination of OV and radiotherapy significantly delayed tumour growth 
and prolonged survival compared to single agent therapy. These data suggest that 
the virally-mediated down-regulation of anti-apoptotic proteins may increase the 
sensitivity of tumour cells to the cytotoxic effects of ionizing radiation. Oncolytic 
virotherapy represents an exciting candidate for clinical development when delivered 
by ILP. Its ability to overcome anti-apoptotic signals within tumour cells points the 
way to further development in combination with conventional anti-cancer therapies.
INTRODUCTION
Surgical resection is the first-line treatment for 
soft tissue sarcomas (STS), as it has the greatest curative 
potential. Radiotherapy has a well-established role in 
securing local disease control and may be given either 
pre- or post-operatively [1, 2]. However, approximately 
half of all patients with intermediate or high-grade STS 
will develop metastatic disease, with a 5-year survival 
of only 50% [1]. With the exception of specific chemo-
sensitive subtypes, systemic chemotherapy has limited 
efficacy either as an adjuvant treatment or in the presence 
of metastatic disease [3, 4]. Therefore, new treatments and 
strategies to overcome treatment resistance are urgently 
needed.
A highly attenuated oncolytic vaccinia virus (VV), 
designated as GL-ONC1 (laboratory name GLV-1h68), 
has been developed [5]. Three expression casettes (RUC-
GFP, LacZ, gusA) were inserted into F14.5L, J2R and 
A56R loci of the viral genome, respectively, resulting in 
attenuated virulence, enhanced tumour-specific targeting, 
and the ability to monitor viral transgene expression. 
In vitro, VV has single agent efficacy against a large range 
of tumour cell lines [5–13] including sarcoma [5, 7, 13].
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The efficacy of the systemic administration of 
oncolytic virotherapy may be diminished by sequestration 
in the reticulo-endothelial system, clearance by circulating 
antibodies or an inability to penetrate the tumour in 
sufficient titres [14]. Intra-tumoural administration of 
virus has been shown to be effective in melanoma [15], 
although this route may be less practical in the presence 
of bulky, deep tumour deposits. Isolated limb perfusion 
(ILP) is a specialised surgical technique typically reserved 
for locally advanced or recurrent extremity sarcomas 
[16]. Due to the exclusion of the perfusion circuit from 
the systemic circulation, it was hypothesised that ILP 
would be an ideal delivery mechanism for oncolytic 
virotherapy, targeting delivery of the virus to the tumour 
whilst affording protection from sequestration. Previous 
work using an in vivo model of ILP confirmed the efficacy 
of this approach, with higher intra-tumoural viral titres 
achieved when VV was delivered by ILP compared with 
intravenous administration [17]. Furthermore, the addition 
of VV to standard ILP resulted in delayed tumour growth 
and prolonged survival [17].
Ionizing radiation is an important treatment 
modality for many solid tumours and can be used as 
single-agent therapy, in combination with radiosensitising 
chemotherapy or as an adjuvant treatment following 
surgical resection. Preclinical data indicate that the 
combination of oncolytic virotherapy (OV) and radiation 
therapy is promising, showing additional or synergistic 
anti-tumour effects in vitro and in vivo [6, 18–22]. 
These studies have resulted in translational phase I/II 
clinical trials [23, 24]. The mechanism of the interaction 
has not been fully elucidated but has the potential 
to be multifaceted: tumour-tropic viruses may act as 
radiosensitising agents, but radiation may also enhance 
viral immune stimulation and oncolysis by increasing 
viral uptake, replication, gene expression and cell death 
in irradiated cells [25]. However, the reported complex 
effects of radiation on viral infectivity, replication, gene 
expression and cytotoxicity mean that detailed mechanistic 
preclinical studies are an essential prerequisite to trials of 
new oncolytic viral agents in combination with radiation 
[6].
As previously stated, radiotherapy plays a vital role 
in the management of advanced extremity sarcoma. The 
possibility that OV may be able to radiosensitise these 
tumours is an exciting prospect but requires thorough 
initial in vitro and in vivo testing, due to the potential 
toxicities of combining these treatments. Assessing the 
compatibility of this novel treatment with radiotherapy 
may reveal exploitable synergistic relationships and 
discovery of a synergistic mechanism that may help in 
the development of combination treatment strategies that 
could potentially be used in the clinical setting [19]. The 
combination of VV and radiation has previously been 
shown to have beneficial therapeutic effects in preclinical 
studies in melanoma, head and neck cancers and glioma 
[6, 18, 19, 22]. GL-ONC1 is currently in clinical trial in 
combination with radiotherapy and cisplatin for locally 
advanced head and neck carcinoma (NCT01584284).
Whilst GLV-1h68 has been shown to have a 
potent anti-tumour effect, the precise mechanism of 
its cytotoxicity is still unclear. Increased cytotoxicity 
of oncolytic viruses was initially thought to be due to 
increased viral replication and, thus, increased tumour cell 
infection and oncolysis. However, data from a number of 
in vitro studies do not support this hypothesis, not only 
for GL-ONC1/GLV-1h68 but also for other OV [19–21, 
26]. One area of recent research has been the role of 
GLV-1h68 in inducing apoptosis, with several studies 
demonstrating an increase in caspase 3 cleavage [6, 13, 
19, 21]. This highlights the possibility that the primary 
mechanism of cell death may be apoptosis. However, the 
pathway of apoptosis induction and the effects of GLV-
1h68 on the apoptotic signalling pathways have not been 
fully elucidated.
In these studies, we aim to determine the efficacy 
of combining oncolytic vaccinia virus with radiotherapy, 
investigate the mechanism of cell death of GLV-1h68 
and to determine if this can be exploited for clinical use 
with external beam radiation therapy (EBRT) to improve 
clinical outcomes.
RESULTS
The viability of GLV-1h68 is not affected at 
clinically relevant doses of EBRT
The direct effect of EBRT on the viability, 
replication competency and transgene expression of GLV-
1h68 was assessed in vitro. GLV-1h68 was treated with 
increasing doses of radiation (0-32Gy). After exposure to 
radiation serial dilutions of virus were added to a confluent 
layer of CV1 cells in a 24-well plate. After 48 hours of 
incubation the viral plaques were detected using X-Gal 
staining (Figure 1A).
After triplicate repeats, the mean number of viral 
plaques per well for the non-irradiated virus was 2.57 X 
104 (95% CI 1.48 – 3.67 X 104) compared to 2.47 X 104 
(95% CI 1.71 – 3.23 X 104) after 32 Gy. After exposure to 
EBRT, no significant difference was found in the number 
of viral plaque forming units (p.f.u.), the macroscopic 
appearance of the plaques or the ability of GLV-1h68 to 
produce LacZ between the non-irradiated virus and any 
of the escalating radiation doses (One-way ANOVA; p= 
0.9874) (Figure 1B).
The cytotoxic effect of EBRT is enhanced when 
combined with GLV-1h68
The cytotoxicity of EBRT and GLV-1h68 alone, or 
in combination, was assessed using the BN175 cell line as 
a prelude to in vivo experiments. BN175 cells were treated 
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with either GLV-1h68 at MOIs of 0.001 – 2 or EBRT 
between 0 to 4 Gy and incubated for 24, 48 or 72 hours.
Evaluation by MTT cell proliferation assay showed 
that GLV-1h68 had a cytotoxic effect on BN175 cells and 
that this increased in a time- and dose-dependent fashion 
(Figure 1C). At 24 and 48 hours, EBRT had no significant 
cytotoxic effect. However, at 72 hours, radiation alone 
showed significant efficacy at 2 Gy, mean survival 87 
% (p < 0.01) and 4 Gy, mean survival 72 % (p < 0.001) 
compared to non-irradiated controls (Figure 1D).
In the combination therapy experiments, BN175 
cells were treated with a range of viral doses and irradiated 
6 hours post-viral treatment with 0, 2, 4 and 8 Gy. On 
analysis at 72 hours, the cytotoxicity of GLV-1h68 at MOI 
Figure 1: GLV-1h68 is not affected by clinically relevant doses of EBRT and shows enhanced cytoxicity against BN175 
cells in combination with EBRT. A. Photograph of viral plaque assay showing GLV-1h68 titration post-treatment with increasing 
doses of irradiation and B. line graph showing quantification of viral titres. MTT analysis of single agent and combination therapy of GLV-
1h68 and EBRT against BN175 cells C. Line graph showing single agent efficacy of GLV-1h68, D. bar graph of single agent efficacy of 
EBRT and E. bar graph of cell survival at 72 hours with combination therapy (** = p value <0.01, *** = p value <0.001).
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of 0.01 was significantly increased when combined with 
2, 4 and 8 Gy compared to viral treatment alone and at an 
MOI of 0.1 the cytotoxicity was significantly increased 
with 4 and 8 Gy (Two-way ANOVA with Bonferroni post-
test; p <0.001). The addition of radiation at higher viral 
MOIs (1 and 10) was not significant and did not further 
enhance the cytotoxicity effect seen in vitro (Figure 1E).
Comparative experiments using a viral MOI of 0.1 
were conducted in a panel of human sarcoma cell lines. 
The combination of GLV-1h68 and radiation resulted in 
significantly increased cytotoxicity in one of three cell 
lines (Supplementary Figure S1).
The combination of EBRT and GLV-1h68 
is at least additive and at best synergistic on 
assessment by long-term clonogenic assay
Colony formation assays are the gold-standard 
method for assessing the effect of radiation in vitro [27]. 
Therefore, colony formation assays were used to test 
the efficacy of the different treatment regimens relative 
to the plating efficiency. The BN175 cell line showed 
sensitivity to radiation alone and in combination with 
GLV-1h68. Furthermore, this cytotoxicity increased in a 
dose-dependent fashion with statistical significance at both 
2 and 4 Gy with a GLV-1h68 MOI of 0.1 and 0.01 (Two-
way ANOVA with Bonferroni post-test; p <0.001), (Figure 
2A, B and 2C).
The presence of synergy between therapies was 
tested using Bliss analysis. This demonstrated that 
combination therapy at 4 Gy had an additive effect and 
that the combination of 2 Gy with GLV-1h68 MOI 0.01 
appeared synergistic (Figure 2D).
The enhanced cytotoxic effect observed when 
combining EBRT and GLV-1h68 is not due to 
accelerated viral replication
To investigate if the observed synergy between 
EBRT and GLV-1h68 was due to increased viral 
replication, the titres of virus present after different 
treatment regimens was assessed by both qPCR, 
measuring A21L expression relative to the house-keeping 
gene 18S, and viral plaque assays (VPA).
On assessment by VPA, the presence of live 
replication-competent GLV-1h68 was not significantly 
increased by radiation therapy at 2, 4 or 8 Gy, compared 
to non-irradiated controls. Conversely, viral replication 
was not abrogated by the effect of radiation alone, with a 
5-fold increase in viral titres from 24 to 48 hours seen at 
all radiation doses (Figure 3A and 3B).
On qPCR, the quantity of GLV-1h68 genomes after 
the different treatment regimens was assessed at 6, 24 and 
48 hours post-treatment. For all treatment groups, this 
showed an expected increase in genome copy numbers over 
the time course of the experiment. With the combination 
of GLV-1h68 and EBRT at 48 hours in comparison to 
virus alone, there was a statistically significant increase 
in viral copy numbers following 2 Gy irradiation (p 
<0.001). However, this significant increase was not found 
with the addition of 4 Gy (p >0.05) and at 8 Gy there 
was a statistically significant decrease in GLV-1h68 copy 
numbers compared to GLV-1h68 treatment alone (p <0.01) 
(Supplementary Figure S2). Taken together, these data 
suggest that the synergistic/additive effects of EBRT and 
GLV-1h68 are not due to altered viral replication.
Combination therapy with GLV-1h68 and 
EBRT increases apoptotic cell death in a dose-
dependent fashion
Having shown that the enhanced cytotoxicity 
between EBRT and GLV-1h68 was independent of viral 
replication, the mechanism of cell death was investigated. 
On western blot analysis, the addition of GLV-1h68 to 
EBRT, at 2 and 4 Gy, resulted in an increase in caspase 
3 cleavage compared to EBRT therapy alone. Serine-15 
is the primary target of the DNA damage response on the 
p53 protein [28] and was used as a marker of ionizing 
radiation-induced DNA damage [29, 30]. With EBRT 
alone, Serine-15 p53 phosphorylation was only apparent at 
4 Gy but did correlate with the presence of cleaved caspase 
3. Interestingly, GLV-1h68 alone was able to induce Serine 
15 phosphorylation of p53 and this significantly increased 
when combined with EBRT at 2 and 4 Gy compared to 
EBRT alone. This coincided with an increase in the level 
of cleaved caspase 3 (Figure 3C).
To validate and quantify the apoptotic response 
to combined therapy, a Caspase-Glo assay was used to 
measure the levels of caspase 3/7 cleavage after different 
treatment regimens. Treatment with radiation increased 
cleaved caspase 3/7 induction at 2 and 4 Gy. Both GLV-
1h68 and EBRT alone induced caspase 3/7 cleavage and 
this induction significantly increased with the combination 
of GLV-1h68 and 4 Gy compared to either agent alone 
(Two-way ANOVA with Bonferroni post-test; p <0.01), 
(Figure 3D).
Combination therapy activates the intrinsic 
apoptotic pathway and downregulates anti-
apoptotic proteins
Apoptosis as the mechanism of cell death was 
further evaluated in the BN175 cell line using western 
blot analysis. Treatment with GLV-1h68 alone induced 
cleavage of caspase 9 at 48 hours post-treatment, which 
was not seen with EBRT alone and no further increase in 
cleaved caspase 9 was seen with the combination of GLV-
1h68 and EBRT. The identification of cleaved caspase 
3 and 9 at 48 hours after treatment suggests that GLV-
1h68 may cause cell death by intrinsic pathway-mediated 
apoptosis (Figure 3E).
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To elucidate further the mechanism of apoptosis, 
the BCL-2 family of proteins was studied to ascertain if 
GLV-1h68 infection had an effect on the critical negative 
regulators of apoptosis. On western blot analysis, untreated 
BN175 cells appeared to have high baseline levels of all 
the inhibitors of apoptosis tested (BCL-XL, Total BCL-2, 
BCL-2 Ser70, BCL-2 Thr56 and MCL-1). The levels of all 
of these proteins, except for MCL-1, were unchanged at 24 
and 48 hours post-treatment with either, GLV-1h68, EBRT 
or combination therapy.
MCL-1, an early critical negative regulator of 
apoptosis, which ultimately prevents the activation of 
mitochondrial cytochrome C release [31, 32] was present 
at high baseline levels in BN175 cells. At 24 hours post-
treatment with GLV-1h68, the levels decreased compared 
to untreated or EBRT only treatment and at 48 hours 
Figure 2: Assessment of combination therapy using colony formation assays revealed a synergistic cytotoxicity with 
GLV-1h68 and EBRT at 2 Gy. A. Bar graph showing increased cytotoxicity with the addition of GLV-1h68 (MOI 0.01) to EBRT. 
B. photograph of clonogenic assay 6-well plates stained with crystal violet 10 days post-treatment. C. Bar Graph of the combination therapy 
with increasing viral MOI’s and EBRT 2 and 4 Gy D. Bliss analysis of combination therapy (GLV-1h68 MOI 0.01, radiation at 2 and 4 Gy). 
(** = p value <0.01 and *** = p value <0.001).
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MCL-1 was undetectable following GLV-1h68 treatment 
alone and combination therapy (Figure 3E).
A panel of human sarcoma cell lines were used 
to validate the observed decrease of MCL-1 in the rat 
fibrosarcoma cell line and to determine if the in vitro 
findings translated to human sarcomas and potentially to 
patients. The SW872 liposarcoma, SW684 fibrosarcoma 
and HT1080 fibrosarcoma cell lines were kindly provided 
by Prof J. Shipley. The cytotoxic effect of GLV-1h68 
single agent therapy on these cell lines has previously 
been reported [13]. The ability of GLV-1h68 to infect 
and produce efficient transgene expression in all the cell 
lines was tested. Cells were plated in a confluent layer 
in individual wells on a 24-well plate and assessed with 
Figure 3: The enhanced cell kill observed in the BN175 cells after treatment with GLV-1h68 and EBRT is not due to 
increased viral replication but mediated via induction of intrinsic apoptosis and downregulation of the anti-apoptotic 
MCL-1 protein. A. Viral plaque assay (VPA) investigating the recovery of live GLV-1h68 at progressive time points post-treatment with 
GLV-1h68 MOI 0.01 (VV) alone or in combination with radiation (0-8 Gy) and B. with GLV1h68 MOI 0.1. C. Western blot analysis of 
cleaved caspase 3 and Serine-15 phosphorylated p53 and D. Caspase-Glo assay of caspase 3/7 activity 48 hours post-combination therapy 
(** = p value <0.01). E. Western blot analysis of BN175 cells 48 hours after treatment with GLV-1h68 (MOI 0.1) and EBRT (4 Gy).
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fluorescence microscopy at 24, 48 and 72 hours for the 
expression of viral GFP. GFP transgene expression was 
consistently detectable at 24 hours post-infection with 
GLV-1h68 (MOI 1) in all cell lines and intensified at 48 
and 72 hours (Figure 4A).
In all three human sarcoma cell lines (SW684, 
SW872 and HT1080), the induction of caspase 3, 9 and 
PARP was investigated. Cleavage of PARP (or loss of 
full length PARP), caspase 9 and caspase 3 was seen after 
treatment with GLV-1h68 alone and in combination with 
EBRT in all cell three lines. This was notably enhanced 
compared to controls or EBRT alone (Figure 4B).
In the human sarcoma cell lines, the anti-apoptotic 
proteins MCL-1 and BCL-XL were not affected by EBRT 
Figure 4: Efficient infection of cells, with the GFP producing GLV-1h68, leads to apoptotic cell death due to the loss 
of the anti-apoptotic MCL-1 protein and the inhibitors of apoptosis (IAPs). A. GFP transgene expression in the rat BN175 
cell line and a panel of human sarcoma cell lines (HT1080, SW684 and SW872) at 24, 48 and 72 hours after treatment with GLV-1h68 
(MOI 1). B. Western blot analysis of 3 human sarcoma cell lines after treatment with GLV-1h68 (MOI 0.1) and EBRT (4 Gy). C. Western 
blot analysis of the expression of anti-apoptotic BCL2 proteins, IAPs and downstream pro-survival signalling pathways 48 hours after 
treatment with GLV-1h68 (MOI 0.1) and EBRT (4 Gy) alone or as combination therapy. The MCL-1 protein was consistently detected at 
40kDa in the human cell lines and at 37kDa in the BN175 rat cell line.
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alone. However, after treatment with virus alone or in 
combination with EBRT, the levels of the anti-apoptotic 
protein BCL-XL were considerably reduced. The level of 
MCL-1 decreased substantially with GLV-1h68 therapy 
alone in the human sarcoma cell lines and showed a 
further decrease when combined with EBRT (Figure 4C).
The inhibitors of apoptosis (IAP) family of proteins 
were also examined. The primary antibodies used (IAP 
Family Antibody Sampler Kit #9770, Cell Signalling) 
were all human-specific except for Survivin. Therefore, 
only levels of Survivin were detectable in the rat BN175 
cell line. All of the IAP proteins tested were expressed in 
the untreated human sarcoma cell lines.
In the SW684 cell line, the protein levels of all of 
the IAPs tested (XIAP, CIAP-1, CIAP-2 and Survivn) 
were unaffected by EBRT alone but decreased with 
GLV-1h68 single agent therapy, with a further decrease 
after combination therapy. In the SW872 cells, EBRT 
alone again had no effect on the level of any of the IAP 
proteins. GLV-1h68 decreased the expression level of all 
IAP proteins but with no further reduction when combined 
with EBRT. GLV-1h68 appeared to have the greatest effect 
on the N-ras mutant HT1080 cells, in which the levels 
of XIAP, CIAP-1, CIAP-2 and Survivin decreased with 
GLV-1h68 alone and were completely undetectable after 
combination therapy with GLV-1h68 and EBRT.
XIAP is reported to activate JNK and NF-κB 
pro-survival signalling within the cell [33]. Therefore, 
to elucidate if the down-regulation of XIAP resulted in 
downstream effects, the levels of NF-κB and pJNK were 
tested. In all of the four cell lines, there was a decrease in 
the levels of both NF-κB p65 and pJNK with GLV-1h68 
treatment alone or in combination with EBRT Figure 4C.
In order to determine whether down-regulation 
of expression was limited to anti-apoptotic proteins 
following treatment with GLV-1h68 and EBRT, the 
levels of the pro-apoptotic proteins Bax and Bak were 
tested. Bak was not expressed in the BN175 cell line and 
its expression in the human sarcoma cell lines was not 
affected by treatment with GLV-1h68 and EBRT alone 
or in combination. The expression of Bax was not found 
to alter in the BN175, SW872 or HT1080 cell lines and 
appeared to be upregulated following treatment with GLV-
1h68, alone or in combination with EBRT, in the SW684 
cell line (Supplementary Figure S3).
Combination therapy with GLV-1h68 delivered 
by ILP and EBRT resulted in prolonged survival 
compared to controls or single agent therapy
The in vivo effects of the combination of EBRT and 
GLV-1h68 delivered by ILP were studied in an orthotopic 
model of advanced extremity sarcoma. Animals were 
engrafted with 1 x 107 BN175 cells prior to undergoing either 
ILP with GLV-1h68 alone or femoral artery and vein ligation, 
followed by EBRT at 48 and 72 hours post-procedure.
A significant delay in tumour growth was seen in 
animals treated with either EBRT or GLV-1h68 single 
agent therapy, with a median increase in time to humane 
endpoint, compared to controls, of 4 and 6 days (33% and 
50%), (one-way ANOVA, Tukey’s post-hoc test p <0.01 
and p <0.001), respectively. Furthermore, the combination 
of GLV-1h68 and EBRT was found to significantly increase 
time to humane endpoint compared to either agent alone 
(one-way ANOVA, Tukey’s post-hoc test p <0.0001). 
Median times to humane endpoints were 12, 16, 18, 
27 days in control, EBRT alone, GLV-1h68 alone and 
GLV-1h68 and EBRT groups, respectively (Figure 5A-5C).
Single agent and combination therapy was well 
tolerated with no evidence of cutaneous or systemic 
toxicity in the any of the animals treated.
DISCUSSION
Previous work with an orthotopic model of extremity 
sarcoma has demonstrated the potential of OV when delivered 
by ILP. The addition of OV to a standard ILP protocol 
resulted in tumour growth delay and prolonged survival 
[13]. However, local disease control was not achieved 
and modifications of this treatment strategy to maximise 
efficacy were sought. Radiotherapy plays a vital role in the 
management of extremity sarcoma and has been shown to be 
synergistic with OV in other tumour models [6, 18–21, 23]. 
The purpose of this study was to determine if the combination 
of OV with radiotherapy is an effective treatment strategy 
when combined with ILP and to investigate the mechanistic 
interactions that may be exploitable for clinical benefit.
As GLV-1h68 is a double stranded DNA virus [34], 
and so potentially vulnerable to the damaging effects of 
ionising radiation, we first determined the effects of EBRT 
on viral viability. GLV-1h68 was found to be resistant to 
radiation at doses far higher than would be used in the 
clinic, up to a maximum of 32 Gy in a single fraction. 
As such, in both the pre-clinical and clinical setting, 
EBRT may be scheduled either before or after delivery 
of vaccinia virus with no effect on therapeutic efficacy. 
This is of particular significance for downstream clinical 
translation, not least of all because the natural sequence 
for combining these modalities would be intravascular 
viral delivery (during ILP) followed by EBRT.
Not only is GLV-1h68 resistant to EBRT, but also 
the combination of these modalities was found to be 
at least additive and possibly synergistic. A small but 
significant increase in cytotoxicity was seen with the 
combination of GLV-1h68 at both 2 and 4 Gy on MTT 
assays. Furthermore, a synergistic effect with the addition 
of GLV-1h68 at 2 Gy and an additive effect at 4 Gy 
were noted on clonogenic assays, the gold-standard for 
assessing the effects of ionising radiation in vitro [27].
Additive or synergistic effects following the 
combination of OV with radiation have been demonstrated 
in a number of pre-clinical models and the mechanisms 
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responsible are likely to be multifactorial. One putative 
mechanism is enhanced oncolysis secondary to a radiation-
induced increase in viral replication [25]. However, there 
are several conflicting studies in the literature concerning 
OV cytotoxicity and correlation to viral replication. 
A number of studies with a range of different viruses 
have suggested that enhanced lytic cytotoxicity is due 
to increased viral replication following combination 
treatment with either radiation or cytotoxic chemotherapy 
[35–37]. However, others have reported no change or even 
a reduction in viral replication in combination regimens 
with radiation or chemotherapy [6, 21, 38–42]. Our 
Figure 5: In an aggressive sarcoma model combination therapy with GLV-1h68 delivered by ILP and adjuvant EBRT 
(13 Gy/2 fractions) prolongs survival and delays tumour growth in Brown Norway rats, bearing BN175 tumours on 
the left hind limb. A. Kaplan Meier curve of survival in each treatment cohort with median time to humane endpoint displayed in group 
legend. B. Table displaying surviving number of animals in each cohort at progressive time points and C. tumour growth volumes as 
determined by external calliper measurement.
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experiments have also shown enhanced cytotoxicity in 
the absence of increased viral replication, adding to the 
existing evidence of an additive interaction between OV 
and radiation that is independent of viral replication.
The precise mechanisms of cell death following 
infection with GLV-1h68 remain to be fully elucidated but 
recent studies have suggested an induction of apoptosis 
may be a critical component [6, 17, 19]. Our data support 
these findings, demonstrating a significant increase in 
caspase cleavage in sarcoma cell lines exposed to this virus. 
Infection with GLV-1h68 was also shown to downregulate 
a number of anti-apoptotic proteins, such as MCL-1, BCL-
XL and the IAP family. Although vaccinia virus has also 
been shown to result in a reduction in a range of cellular 
transcripts [43], a reduction in the pro-apoptotic proteins 
Bak and Bax was not seen. In fact, in one cell line Bax 
was up-regluated after treatment with GLV-1h68. These 
data suggest that infection with GLV-1h68 preferentially 
downregulates anti-apoptotic proteins, resulting in an 
overall shift in protein expression within the cell tipping the 
balance in favour of apoptosis (Figure 6). A further decrease 
in the expression of anti-apoptotic proteins was noted when 
GLV-1h68 was combined with EBRT compared with either 
modality alone. This may represent a radiosensitising 
effect following viral infection. Ionising radiation results in 
DNA damage, which, if irreparable, triggers cell death via 
apoptosis. Viral proteins have the potential to interact with 
a number of intracellular signalling pathways regulating 
apoptosis that are triggered by radiation, with vaccinia 
implicated in manipulation of the TNF/JNK, MAPK and 
Akt pathways [6, 44–46]. It may be that interference with 
one or a number of these pathways are responsible for 
the additive effects seen, and the precise nature of this 
interaction warrants further study.
Figure 6: Simplified schematic demonstrating the postulated interactions of GLV-1h68 on the intrinsic apoptotic 
pathway proteins. When activated by an apoptotic stimuli the intrinsic apoptosis pathway causes accelerated degradation of the anti-
apoptotic BCL-2 proteins (BCL-2, BCL-XL, BCL-W and MCL-1) resulting in activation of the pro-apoptotic BH3 only proteins (PUMA, 
NOXA, BID, BIM, BAD, BAX and BAK). This results in initiation and propagation of the effector caspases 3 and 7. In cancer cells 
apoptosis is circumvented through overexpression of the anti-apoptotic BCL-2 proteins and the IAPs. Treatment with GLV-1h68 restores 
the cells ability to undergo apoptosis by inhibiting the overexpression of these negative regulators of apoptosis.
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Despite engendering a pro-apoptotic state in our 
experiments, vaccinia virus is also known to encode 
several proteins that prevent apoptosis [47]. Furthermore, 
in other preclinical models, infection with vaccinia virus 
has been shown to be capable of inducing necrosis and 
necroptosis [48–51]. The effects of combining OV and 
radiation on the relative proportion of cells dying from 
necrosis or necroptosis in our cell lines is unknown and 
further work will be directed at investigating whether the 
promotion of apoptosis is accompanied by a reduction in 
cell death by other means.
Our in vitro findings translated into a therapeutic 
effect in vivo. Using this aggressive limb sarcoma model, 
the combination of delivering GLV-1h68 by ILP and 
EBRT significantly improved survival and proved to be far 
superior to single agent therapy. This effect was beyond 
what would be expected from a simply additive effect. 
This is promising as it means that OV and radiotherapy 
can potentially be combined with currently used ILP 
therapeutics (melphalan and TNF-α) and/or surgical 
resection in an attempt to produce a curative therapeutic 
regimen in preclinical models. Importantly, this would 
have significant translational potential in the clinic.
MATERIALS AND METHODS
In vitro studies
Cell lines
The BN175 rat sarcoma cell line was donated by 
Prof. A. Eggermont. This cell line is tumorigenic in Brown 
Norway rats [52]. Cells were passaged in Dulbecco’s 
Modified Eagle’s Medium (DMEM), supplemented with 5% 
heat-inactivated foetal calf serum (FCS), 2.5% L-glutamine 
and 1% penicillin/streptomycin. The CV-1 monkey kidney 
cell line was obtained from existing laboratory stocks and 
passaged in standard Dulbecco’s Modified Eagle’s Medium 
(DMEM), with 10% FCS, 2.5% L-glutamine and 1% 
penicillin/streptomycin. The HT1080, SW684 and SW872 
human sarcoma cell lines were obtained by donation 
from Dr Janet Shipley and cultured in similarly modified 
DMEM media. Cells were cultured at 37 °C in an incubator 
maintaining a 10% carbon dioxide atmosphere.
Oncolytic vaccinia virus
GLV-1h68 was produced and provided by Genelux 
Corporation (San Diego, USA) as described previously 
[12]. Briefly, three expression cassettes encoding Renilla 
luciferase-GFP fusion protein, β-galactosidase, and 
β-glucuronidase were recombined into the F14.5L, J2R 
and A56R loci, respectively, of the parental Lister strain, 
LIVP, virus genome.
External beam radiotherapy (EBRT)
All irradiations were performed using an Orthovoltage 
X-ray source (320/250 kV; serial no: 20090606) (AGO 
X-Ray Ltd, Reading, UK) at 250 kVp and at a dose rate 
of approximately 0.6 Gy/min, as measured directly by a 
UNIDOS©E Universal Dosimeter (PTW, Grantham, UK). 
Cells were irradiated in 6-, 24- or 96-well plates (Nunc) 
in single fractions up to 8 Gy. Eppendorf tubes containing 
GLV-1h68 at 1 x 105 p.f.u were irradiated at 0, 2, 4, 8, 16 
and 32 Gy.
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay
Estimation of cell proliferation after exposure 
to cytotoxic agents alone or in combination was 
performed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay [53]. Cells 
were plated in a clear-walled 96-well plate (Nunc, 
Denmark) at a density of 2500 cells per well. GLV-1h68 
was added after 16 hours and the cells were irradiated 6 
hours after viral infection. MTT reagent was added at the 
time points indicated. The absorbance of a solution (in 
dimethyl sulfoxide, DMSO) of the reduced MTT was read 
on a plate reader (Victor 2, Perkin Elmer, Mass., USA) 
at a wavelength of 550 nm. Results were normalised 
to a control population of untreated cells. Cell kill was 
calculated as (100 – surviving fraction) %.
Viral plaque assay (VPA)
BN175 cells were plated at 1 × 105 per well in 24-
well plates. Plates were treated with GLV-1h68 (MOI 
0.01 or 0.1) and then incubated for 6 hours before being 
irradiated at 0, 2, 4 or 8 Gy. Supernatant and cells were 
collected at 24 and 48 hours post-infection and the viral 
particles from the infected cells were released by 3 freeze-
thaw cycles and then stored at -80 °C.
CV-1 cells were grown to confluence on 24-
well plates. The supernatants were thawed, and then 
incubated on the CV-1 cells. After 48 hours of incubation, 
virus detection was carried out on the cell monolayer. 
Briefly, cells were fixed with 2% formaldehyde/0.2% 
glutaraldehyde solution for 5 minutes, then washed in PBS 
and stained for 4 hours with X-Gal staining buffer and 
X-Gal (CalBioChem, Merck KGaA, Germany) (1:100). 
Finally, they were washed with UF water and dried.
Macroscopic X-gal-stained viral plaques were 
counted manually. Detected levels were normalised 
according to the proportion of surviving cells, as 
determined by sulphorhodamine B (SRB) assay carried 
out simultaneously.
In a second experiment to determine the potential 
cytotoxic effect of EBRT on GLV-1h68, 1 x 105 plaque-
forming units (PFU) of virus in 1 mL of PBS, was 
irradiated in Eppendorf tubes at 0-32 Gy before being 
added to confluent CV-1 cells. Virus detection was carried 
out after 48 hours of incubation and the number of viral 
plaques counted manually.
Clonogenic assay
BN175 cells were plated at 5 × 105 cells in a T25 
flask and then incubated at 37°C. After 16 hours, the cells 
were treated with GLV-1h68 MOI 0.01 or 0.1 and left in 
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the incubator for a further 48 hours. The cells were then 
washed, trypsinized and counted using a haemocytometer 
and added to 6-well plates, at seeding densities from 200 
to 800 cells per well, in 5 mL of medium with 10% FCS 
added to each well. Sixteen hours after plating, cells were 
irradiated at 0, 2, 4, 6 or 8 Gy, and then incubated at 37°C.
After 10 days, cells were fixed, stained and the 
number of colonies per well counted. The plating 
efficiency of the experiment was determined from the 
control wells and calculated for every experiment. The 
surviving fraction of cells after treatment was calculated 
by normalising the number of colonies per well to the 
plating efficiency.
Bliss analysis
To investigate the cytotoxic effect Bliss 
independence analysis was used as previously described 
[54–57]. Briefly, this methodology uses the formulae 
E
IND
 = EA + EB − EA × EB and ΔE = EOBS − EIND where: 
EA and EB are the fractional effect of factors A and B, 
respectively; E
IND
 is the expected effect of an independent 
combination of factors; E
OBS
 is the observed effect of the 
combination. If ΔE and its 95% confidence interval (CI) 
are >0, synergy has been observed. If ΔE and its 95% 
CI are <0, antagonism has been observed. If ΔE and its 
95% CI contain 0 then the combination is independent. 
A recently published modification of Bliss independence 
analysis could not be used because of the number of 
variables within our dataset [58].
qPCR
Samples were collected as per viral plaque assay 
methods. A21L expression qPCR using the Genelux 
GL-LC1 VV-A21L kit was used for quantitative 
detection of the vaccinia A21L gene. DNA was 
prepared from the lysate of BN175 cells following 
infection with GLV-1h68 (MOI 0.1) and irradiation (0, 
2, 4, 6 or 8 Gy) at 6 hours post-infection and collected 
at 6, 24 and 48 hours post-treatment. A21L specific 
primers were used (forward: 5′-CGTAAACTACA
AACGTCTAAACAAGAA-3′ and reverse: 5′-CCT 
GGTATATCGTCTCTATCTTTATCAC-3′). The 18S 
rRNA of human/rat genomic DNA (18S) was used as a 
reference to determine the copy number ratio of virus.
Western blot analysis
Cells were plated at 5 × 105 in 60 mm dishes. 
Following various treatments, cells were harvested at 
48 hrs in ice-cold PBS, pelleted and resuspended in 
radioimmunoprecipitation assay buffer (50 mM Tris 
(pH 7.5), 150 mM NaCl, 1% NP40, 0.5% sodium 
deoxycholate, and 0.1% SDS) with protease inhibitors 
(Roche Diagnostics GmbH, Mannheim, Germany), 1 
mM sodium orthovanadate (Sigma), and 10 mM sodium 
fluoride. Cells were then lysed by snap-freezing on dry ice 
and then allowing the lysate to thaw on ice for 10 minutes. 
The lysate was then centrifuged at 13,200 rpm/4°C for 20 
minutes to remove cell debris. Protein concentration was 
determined using the BCA protein assay (Pierce, Rockford, 
IL). Thirty μg of each protein sample were resolved on 
SDS-polyacrylamide gels (10-12%) and transferred 
to a polyvinylidene difluoride Hybond-P membrane. 
Immunodetections were performed using procaspase, 
cleaved caspase 3, cleaved caspase 9, phospho-p53 
(Ser15), P-JNK (Thr183/Tyr185), Pro-survival Bcl-2 family 
antibody sampler kit, IAP family antibody sampler 
kit (Cell Signalling Technology), PARP and NF-KB 
(p65) (Santa Cruz Biotechnology Inc) rabbit polyclonal 
antibody in conjunction with a horseradish peroxidase 
(HRP)-conjugated anti-rabbit secondary antibody 
(GE-Healthcare). Equal loading was assessed using 
glyceraldehyde-3-phosphate dehydrogenase-GAPDH 
(Cell Signaling). The Super Signal chemiluminescent 
system (Pierce) or Immobilon Western chemiluminescent 
HRP substrate (Millipore) were used for detection.
Caspase-Glo assay
The Caspase-Glo 3/7 Assay (Promega) was used 
according to the manufacturer’s instructions to determine 
the relative levels of Caspase 3/7 activation 48 hours 
post-infection with GLV-1h68 (MOI 0.1) +/- radiation (2 
or 4 Gy). Detected levels were normalised according to 
proportion of surviving cells, as determined by a duplicate 
MTT assay carried out simultaneously.
In vivo studies
Animals
Inbred, specific pathogen-free adult male Brown 
Norway rats weighing between 225 and 275 g were 
obtained from Charles River (Margate, UK). They 
were housed in compliance with all relevant regulatory 
requirements and fed standard chow and water ad libitum.
Tumour response experiments
All in vivo experiments were performed with 
bioethical approval from the British Home Office. Animals 
were randomly allocated to one of four treatment groups, 
containing six rats per group. Control, EBRT 13 Gy in two 
fractions, Isolated limb perfusion (ILP) with GLV-1h68 
(1 x 107 PFU) and ILP with GLV-1h68 (1x 107 PFU) and 
adjuvant irradiation at 13 Gy in two fractions.
BN175 cells (1 x 107 cells in 500 μL PBS) were 
injected into the left hind limb of the rat. ILP was 
performed on day 6 after cell injection. The ILP technique 
was a modified version of a previously reported method 
[59]. Animals underwent either femoral artery and vein 
ligation (controls and EBRT only) or ILP with GLV-1h68 
1 x 107 plaque forming units (pfu). Therapeutic perfusion 
was performed for 13 minutes and washout for 2 minutes.
Rats were irradiated, on both day 8 and 9 post-
tumour engraftment to a total dose of 13 Gy. Before 
therapeutic tumour irradiation, rats received an 
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intraperitoneal injection of a 1:1:2 solution of hypnorm 
(Janssen Pharmaceutical Ltd.), hypnovel (Roche), and 
sterile water. The resulting mixture contains 1.25 mg/
mL midazolam, 2.5 mg/mL fluanisone and 0.079 mg/
mL fentanyl citrate and is administered as a single 
intraperitoneal injection of 1.5 mL/kg bodyweight 
and titrated as required to a maximal dose of 3 mL/
kg bodyweight. Anaesthetised animals were placed in a 
custom-made 6 mm lead shield. The shield holds the leg 
abducted from the midline, such that the tumour may be 
irradiated through a window, whilst minimising irradiation 
of surgical wound site, visceral or other structures. To 
quantify the radiation dose delivered to the tissues a 
universal dosimeter was placed adjacent to the tumour 
during irradiation.
Tumour growth and humane endpoints
Tumour growth was assessed every 48 hours 
by direct calliper measurement in two orthogonal; 
dimensions. Tumour volume was calculated using 
the formula: Volume = ½(width2 x breadth). Animals 
were culled at a pre-specified humane endpoint of 2 
cm maximum tumour diameter. An additional humane 
endpoint of >10% weight loss was also defined but not 
reached in this study.
Statistical analysis
Simple and descriptive statistical analysis was 
performed using Microsoft Excel (Microsoft Inc, 
Washington, USA). Kaplan-Meier survival analysis and 
group analysis, including ANOVA, was performed using 
GraphPad Prism software (GraphPad Software Inc, 
California, USA). Statistical significance was defined 
as a p-value of less than 0.05. Error bars on all graphs 
represent standard error of the mean.
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